Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...

Novavax on Wednesday beat Wall Street estimates for first-quarter revenue, as milestone payments from vaccine ​supply and ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) beat Wall Street’s revenue expectations in Q1 CY2026, but sales fell by ...

Novavax (NVAX) shares added ~6% in the premarket on Wednesday after the COVID-19 vaccine maker well exceeded Street forecasts with its Q1 financials, thanks to a licensing deal with Pfizer (PFE) ...

Good morning, and thank you all for joining us today to discuss our second quarter 2025 financial results and operational highlights. Before we begin with prepared remarks, I need to remind you that ...

Quote (Executive VP, CFO & Treasurer Kelly): “Nuvaxovid product sales of $10 million was primarily driven by sales into Germany for the 2025-2026 season and reflects the completion of Novavax’s ...

(NVAX) on Wednesday reported a loss of $9.5 million in its first quarter. On a per-share basis, the ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter from the agency, but only for people 65 and older and those 12 and up who ...

Add Yahoo as a preferred source to see more of our stories on Google. Food and Drug Administration commissioner Martin Markary speaks during an event in the Roosevelt Room at the White House, Monday, ...

Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, ...

Novavax on ​Wednesday ‌beat Wall Street estimates for ‌first-quarter ​revenue, ⁠as milestone ⁠payments from vaccine supply ...